Science & Technology
Validating SER-014, a TRPV1 antagonist, to treat endometriosis
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R41HD115418-01
Award Ceiling
$384K
Award Floor
$384K
Close Date
Aug 31, 2025
Total Funding
$384K
Expected Awards
1
Posted Date
Sep 1, 2024
Cost Sharing Required
No
Grants.gov ID
sbir-1R41HD115418-01
Description
STTR Phase Phase I award: "Validating SER-014, a TRPV1 antagonist, to treat endometriosis" awarded to Serentrix LLC in Exton, Pennsylvania. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $384,418. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses, Socially/economically disadvantaged
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.